Tauromustine | CAS#85977-49-7 | Antineoplastic Agent

MedKoo Cat#: 599284 | Name: Tauromustine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tauromustine is a compound being used in the research of slow-release antitumor gel injections

Chemical Structure

Tauromustine

CAS#85977-49-7

Theoretical Analysis

MedKoo Cat#: 599284

Name: Tauromustine

CAS#: 85977-49-7

Chemical Formula: C7H15ClN4O4S

Exact Mass: 286.0503

Molecular Weight: 286.73

Elemental Analysis: C, 29.32; H, 5.27; Cl, 12.36; N, 19.54; O, 22.32; S, 11.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Tauromustine; LS-2667; LS 2667; LS2667; Tauromustinum; TCNU;

IUPAC/Chemical Name

2-(3-(2-chloroethyl)-3-nitrosoureido)-N,N-dimethylethane-1-sulfonamide

InChi Key

RCLLNBVPCJDIPX-UHFFFAOYSA-N

InChi Code

InChI=1S/C7H15ClN4O4S/c1-11(2)17(15,16)6-4-9-7(13)12(10-14)5-3-8/h3-6H2,1-2H3,(H,9,13)

SMILES Code

O=C(NCCS(=O)(N(C)C)=O)N(CCCl)N=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 286.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gregor A, Rampling R, Aapro M, Malmström P, Whittle IR, Rye R, Stewart M, Sellar R, Demierre B, Ironside JW, et al. Phase II study of tauromustine in malignant glioma. Eur J Cancer. 1992;28A(12):1959-62. PubMed PMID: 1419289. 2: Hartley-Asp B. Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro. Mutagenesis. 1992 Nov;7(6):427-31. PubMed PMID: 1474918. 3: Singh G, Graffner HO, Milsom JW, Chaudry IH. Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors. Dis Colon Rectum. 1993 Apr;36(4):394-9. PubMed PMID: 8458268. 4: Tuvesson H, Gunnarsson PO, Seidegård J. Metabolism of tauromustine in liver and lung microsomes from various species. Xenobiotica. 1999 Aug;29(8):783-92. PubMed PMID: 10553719. 5: Smyth JF, Hardcastle JD, Denton G, Alderson D, Grace RH, Mansi JL, Yosef HM, Nordle O, Lauri H, Wählby S. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol. 1995 Nov;6(9):948-9. PubMed PMID: 8624301. 6: Gunnarsson PO, Vibe-Petersen J, Macpherson JS, Warrington PS, Polacek J, Ellman M, Hansen HH, Smyth JF. Pharmacokinetics of tauromustine in cancer patients. Phase I studies. Cancer Chemother Pharmacol. 1989;23(3):176-80. PubMed PMID: 2924375. 7: Seidegård J, Grönquist L, Gunnarsson PO. Metabolism of a novel nitrosourea, tauromustine, in the rat. Biochem Pharmacol. 1990 May 1;39(9):1431-6. PubMed PMID: 2334443. 8: Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, Söderberg M, Wählby S. Phase I study of tauromustine administered in a weekly schedule. Eur J Cancer. 1993;29A(13):1901-2. PubMed PMID: 8260251. 9: Polacek J, Gunnarsson PO, Brandin S. Determination of tauromustine, a nitrosourea-based antitumour agent, in plasma by high-performance liquid chromatography. J Chromatogr. 1988 Mar 18;425(2):424-8. PubMed PMID: 3372655. 10: Nolte H, Gjedde SB, Lindegaard-Madsen E, Bergh J, Blomquist E, Mouridsen HT. Phase II study of tauromustine in disseminated malignant melanoma. Eur J Cancer Clin Oncol. 1989 Apr;25(4):655-7. PubMed PMID: 2714342. 11: Whittle IR, MacPherson JS, Miller JD, Smyth JF. The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications. J Neurosurg. 1990 May;72(5):721-5. PubMed PMID: 2157825. 12: Taal BG, Ten Bokkel Huinink WW, Rodenhuis S. Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer. Eur J Cancer. 1993;29A(13):1916-7. PubMed PMID: 8260256. 13: Hill SR, Pollard LA, Bibby MC. Sequence-dependent activity of 5-fluorouracil plus tauromustine in a transplantable well-differentiated murine colon adenocarcinoma. Anticancer Res. 1992 Nov-Dec;12(6B):2169-75. PubMed PMID: 1295464. 14: Roos G, el Hag IA, Christensson PI, Stenram U. The antitumor effect of a novel nitrosourea, tauromustine, at intravenous administration in rat. Cure of hepatomas. Anticancer Res. 1991 Sep-Oct;11(5):1763-6. PubMed PMID: 1837442. 15: Taal BG, ten Bokkel Huinink WW, Franklin HR, McVie JG. 5-Fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results. Eur J Cancer. 1990;26(7):856. PubMed PMID: 2145919. 16: Gatzemeier U, Drings P, Edler L, Fiebig HH, Hinke A, Rieche K, Tessen HW. Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society. Onkologie. 1990 Jun;13(3):186-8. PubMed PMID: 2168534. 17: Polacek J, Gustafsson B, Brandin S, Ottersgård-Brorsson A. Determination of tauromustine and its demethylated metabolites in plasma and urine. J Chromatogr. 1990 Mar 16;526(1):151-7. PubMed PMID: 2341526. 18: Taal BG, ten Bokkel Huinink WW, Rodenhuis S. Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study. Ann Oncol. 1993 Jan;4(1):81-2. PubMed PMID: 8435369. 19: Loftsson T, Baldvinsdóttir J. Degradation of tauromustine (TCNU) in aqueous solutions. Acta Pharm Nord. 1992;4(3):129-32. PubMed PMID: 1418640. 20: Gjedde SB, Mouridsen HT, L-Madsen E, Jensen NV, Blomquist E, Bergh J, Söderberg M, Wählby S. Phase II study of tauromustine in disseminated malignant melanoma. Eur J Cancer. 1994;30A(4):566. PubMed PMID: 8018421.